Skip Navigation



JAC Advance Access published online on January 16, 2004

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh082
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/2/305    most recent
dkh082v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Flatz, L.
Right arrow Articles by Cottagnoud, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flatz, L.
Right arrow Articles by Cottagnoud, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 The British Society for Antimicrobial Chemotherapy

Original article

Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci

L. Flatz 1 , M. Cottagnoud 1 , F. Kühn 1 , J. Entenza 2 , A. Stucki 3 , and P. Cottagnoud 3 *

1 Department of Internal Medicine, Spital Bern-Ziegler, Bern;
2 Department of Infectious Diseases, CHUV, Lausanne;
3 Department of Internal Medicine, Inselspital, Bern, Switzerland

* Corresponding author. E-mail: pcottagn{at}insel.ch.

Received 13 April 2003 ; revised 15 November 2003 ; accepted 17 November 2003

Abstract

Ceftriaxone acted synergistically with levofloxacin in time-killing assays in vitro over 8 h against two penicillin-resistant pneumococcal strains (WB4 and KR4; MIC of penicillin: 4 mg/L). Synergy was confirmed with the chequerboard method, showing FIC indices of 0.25. In the experimental rabbit meningitis model, ceftriaxone (1x 125 mg/kg) was slightly less bactericidal (-0.30 {Delta}log10 cfu/mL.h) compared with levofloxacin (-0.45 {Delta}log10 cfu/mL.h) against the penicillin-resistant strain WB4. The combination therapy (levofloxacin and ceftriaxone) was significantly superior (-0.64 {Delta}log10 cfu/mL.h) to either monotherapy. In cycling experiments in vitro, the addition of ceftriaxone at a sub-MIC concentration (1/16 MIC) reduced levofloxacin-induced resistance in the two strains KR4 and WB4. After 12 cycles with levofloxacin monotherapy, the MIC increased 64-fold in both strains versus a 16-fold increase with the combination (levofloxacin + ceftriaxone 1/16 MIC). In both strains, levofloxacin-induced resistance was confirmed by mutations detected in the genes parC and gyrA, encoding for subunits of topoisomerase IV and gyrase, respectively. The addition of ceftriaxone suppressed mutations in parC but led to a new mutation in parE in both strains.

Keywords: Streptococcus pneumoniae, quinolones, {beta}-lactam antibiotics
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
P. Cottagnoud, M. Johnson, M. Cottagnoud, and L. Piddock
Preincubation of Pneumococci with {beta}-Lactams Alone or Combined with Levofloxacin Prevents Quinolone-Induced Resistance without Increasing Intracellular Levels of Levofloxacin
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3517 - 3519.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Shang, L. Xia, M. Zhong, J. Zhang, J. Zhao, X. Gong, D. Mabey, and Q. Wang
In Vitro Effects of Spectinomycin and Ceftriaxone Alone or in Combination with Other Antibiotics against Chlamydia trachomatis
Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1584 - 1586.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.